SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jun Peng, Yi Huan, Qian Jiang, Su-juan Sun, Chun-ming Jia, Zhu-fang Shen, Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice, PPAR Research, 2014, 2014, 1

    CrossRef

  2. 2
    Eleonora Scorletti, Lokpal Bhatia, Keith G. McCormick, Geraldine F. Clough, Kathryn Nash, Leanne Hodson, Helen E. Moyses, Philip C. Calder, Christopher D. Byrne, Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study, Hepatology, 2014, 60, 3
  3. 3
    Isao Okazaki, Takuji Noro, Nobuhiro Tsutsui, Eigoro Yamanouchi, Hajime Kuroda, Masayuki Nakano, Hiroaki Yokomori, Yutaka Inagaki, Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs), Cancers, 2014, 6, 3, 1220

    CrossRef

  4. 4
    Siddharth Singh, Alina M. Allen, Zhen Wang, Larry J. Prokop, Mohammad H. Murad, Rohit Loomba, Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies, Clinical Gastroenterology and Hepatology, 2014,

    CrossRef

  5. 5
    Maud Lemoine, Lawrence Serfaty, Pascale Cervera, Jacqueline Capeau, Vlad Ratziu, Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage, Hepatology Research, 2014, 44, 8
  6. 6
    Norbert Stefan, Markus Ramsauer, Paul Jordan, Bettina Nowotny, Konstantinos Kantartzis, Jürgen Machann, Jong-Hee Hwang, Peter Nowotny, Sabine Kahl, Jürgen Harreiter, Silke Hornemann, Arun J Sanyal, Paul M Stewart, Andreas F Pfeiffer, Alexandra Kautzky-Willer, Michael Roden, Hans-Ulrich Häring, Sabine Fürst-Recktenwald, Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial, The Lancet Diabetes & Endocrinology, 2014, 2, 5, 406

    CrossRef

  7. 7
    Amirhossein Sahebkar, Gerard T Chew, Gerald F Watts, New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease, Expert Opinion on Pharmacotherapy, 2014, 15, 4, 493

    CrossRef

  8. 8
    Vikram Prasad, Shivani Chirra, Rohit Kohli, Gary E. Shull, NHE1 deficiency in liver: Implications for non-alcoholic fatty liver disease, Biochemical and Biophysical Research Communications, 2014, 450, 2, 1027

    CrossRef

  9. 9
    A. J. Czaja, Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis, Alimentary Pharmacology & Therapeutics, 2014, 39, 4
  10. You have free access to this content10
    Z. M. Younossi, M. J. Reyes, A. Mishra, R. Mehta, L. Henry, Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets, Alimentary Pharmacology & Therapeutics, 2014, 39, 1
  11. 11
    Natalia Mazzella, Laura M. Ricciardi, Arianna Mazzotti, Giulio Marchesini, The Role of Medications for the Management of Patients with NAFLD, Clinics in Liver Disease, 2014, 18, 1, 73

    CrossRef

  12. You have free access to this content12
    A. Consoli, G. Formoso, Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?, Diabetes, Obesity and Metabolism, 2013, 15, 11
  13. 13
    Detlef Schuppan, Yong Ook Kim, Evolving therapies for liver fibrosis, Journal of Clinical Investigation, 2013, 123, 5, 1887

    CrossRef

  14. 14
    Yanlan Zhou, Shi Jia, Chunjiong Wang, Zhenzhen Chen, Yujing Chi, Jing Li, Guoheng Xu, Youfei Guan, Jichun Yang, FAM3A is a target gene of peroxisome proliferator-activated receptor gamma, Biochimica et Biophysica Acta (BBA) - General Subjects, 2013, 1830, 8, 4160

    CrossRef

  15. 15
    Scott L. Friedman, Focus, Journal of Hepatology, 2013, 59, 5, 915

    CrossRef

  16. 16
    Hikaru Satoh, Naohito Ide, Yoshiyuki Kagawa, Toshio Maeda, Hepatic Steatosis with Relation to Increased Expression of Peroxisome Proliferator-Activated Receptor-γ in Insulin Resistant Mice, Biological and Pharmaceutical Bulletin, 2013, 36, 4, 616

    CrossRef

  17. 17
    Bart Staels, Anne Rubenstrunk, Benoit Noel, Géraldine Rigou, Philippe Delataille, Lesley J. Millatt, Morgane Baron, Anthony Lucas, Anne Tailleux, Dean W. Hum, Vlad Ratziu, Bertrand Cariou, Rémy Hanf, Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, Hepatology, 2013, 58, 6
  18. 18
    KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease, Clinical and Molecular Hepatology, 2013, 19, 4, 325

    CrossRef

  19. 19
    Patrizia Burra, Liver abnormalities and endocrine diseases, Best Practice & Research Clinical Gastroenterology, 2013, 27, 4, 553

    CrossRef

  20. 20
    Angel Brea, José Puzo, Non-alcoholic fatty liver disease and cardiovascular risk, International Journal of Cardiology, 2013, 167, 4, 1109

    CrossRef

  21. 21
    Sanjaya Kumar Satapathy, Satheesh Nair, Jason M. Vanatta, Nonalcoholic fatty liver disease following liver transplantation, Hepatology International, 2013, 7, 2, 400

    CrossRef

  22. 22
    Howard C. Masuoka, Naga Chalasani, Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals, Annals of the New York Academy of Sciences, 2013, 1281, 1
  23. 23
    Barbara Fruci, Stefania Giuliano, Angela Mazza, Roberta Malaguarnera, Antonino Belfiore, Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment, International Journal of Molecular Sciences, 2013, 14, 11, 22933

    CrossRef

  24. 24
    Feng Zhang, Desong Kong, Yin Lu, Shizhong Zheng, Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside, Cellular and Molecular Life Sciences, 2013, 70, 2, 259

    CrossRef

  25. 25
    Scott S. Malinowski, Jennifer S. Byrd, Allison M. Bell, Marion R. Wofford, Daniel M. Riche, Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013, 33, 2
  26. 26
    Vlad Ratziu, Pharmacological agents for NASH, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 11, 676

    CrossRef

  27. 27
    Maeva Guillaume, Vlad Ratziu, Pharmacological agents for nonalcoholic steatohepatitis, Hepatology International, 2013, 7, S2, 833

    CrossRef

  28. 28
    Chih-Wen Lin, Hao Zhang, Min Li, Xiwen Xiong, Xi Chen, Xiaoyun Chen, Xiaocheng C. Dong, Xiao-Ming Yin, Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice, Journal of Hepatology, 2013, 58, 5, 993

    CrossRef

  29. 29
    J. H. Lewis, J. G. Stine, Review article: prescribing medications in patients with cirrhosis – a practical guide, Alimentary Pharmacology & Therapeutics, 2013, 37, 12
  30. 30
    Hanford Yau, Kathya Rivera, Romina Lomonaco, Kenneth Cusi, The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus, Current Diabetes Reports, 2013, 13, 3, 329

    CrossRef

  31. 31
    Simon Ducheix, Alexandra Montagner, Vassilia Theodorou, Laurent Ferrier, Hervé Guillou, The liver X receptor: A master regulator of the gut–liver axis and a target for non alcoholic fatty liver disease, Biochemical Pharmacology, 2013, 86, 1, 96

    CrossRef

  32. 32
    Detlef Schuppan, Massimo Pinzani, Anti-fibrotic therapy: Lost in translation?, Journal of Hepatology, 2012, 56, S66

    CrossRef

  33. 33
    Dawn M. Torres, Christopher D. Williams, Stephen A. Harrison, Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, 2012, 10, 8, 837

    CrossRef

  34. 34
    Maud Lemoine, Lawrence Serfaty, Jacqueline Capeau, From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients, Current Opinion in Infectious Diseases, 2012, 25, 1, 10

    CrossRef

  35. 35
    Pierre Bedossa, Christine Poitou, Nicolas Veyrie, Jean-Luc Bouillot, Arnaud Basdevant, Valerie Paradis, Joan Tordjman, Karine Clement, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 2012, 56, 5
  36. 36
    G. Musso, M. Cassader, F. Rosina, R. Gambino, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials, Diabetologia, 2012, 55, 4, 885

    CrossRef

  37. 37
    Thuy-Anh Le, Rohit Loomba, Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis, Journal of Clinical and Experimental Hepatology, 2012, 2, 2, 156

    CrossRef

  38. 38
    Suzanne E. Mahady, Jacob George, Management of Nonalcoholic Steatohepatitis, Clinics in Liver Disease, 2012, 16, 3, 631

    CrossRef

  39. 39
    Ana C. TUYAMA, Charissa Y. CHANG, Non-alcoholic fatty liver disease, Journal of Diabetes, 2012, 4, 3
  40. 40
    Angelo H. Paredes, Dawn M. Torres, Stephen A. Harrison, Nonalcoholic Fatty Liver Disease, Clinics in Liver Disease, 2012, 16, 2, 397

    CrossRef

  41. 41
    Anthony S. Wierzbicki, Jude Oben, Nonalcoholic fatty liver disease and lipids, Current Opinion in Lipidology, 2012, 23, 4, 345

    CrossRef

  42. 42
    Sandra Milic, Davor Štimac, Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment, Digestive Diseases, 2012, 30, 2, 158

    CrossRef

  43. 43
    Kenneth Cusi, Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications, Gastroenterology, 2012, 142, 4, 711

    CrossRef

  44. 44
    Anne Tailleux, Kristiaan Wouters, Bart Staels, Roles of PPARs in NAFLD: Potential therapeutic targets, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012, 1821, 5, 809

    CrossRef

  45. 45
    Naga Chalasani, Zobair Younossi, Joel E Lavine, Anna Mae Diehl, Elizabeth M Brunt, Kenneth Cusi, Michael Charlton, Arun J Sanyal, The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, The American Journal of Gastroenterology, 2012, 107, 6, 811

    CrossRef

  46. 46
    Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal, The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology, 2012, 142, 7, 1592

    CrossRef

  47. You have free access to this content47
    Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal, The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 2012, 55, 6
  48. 48
    Ali Akbar Hajiaghamohammadi, Amir Ziaee, Rasoul Samimi, The Efficacy of Licorice Root Extract in Decreasing Transaminase Activities in Non-alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial, Phytotherapy Research, 2012, 26, 9
  49. 49
    Bertrand Cariou, Bernard Charbonnel, Bart Staels, Thiazolidinediones and PPARγ agonists: time for a reassessment, Trends in Endocrinology & Metabolism, 2012, 23, 5, 205

    CrossRef

  50. 50
    Valerio Nobili, Arun J. Sanyal, Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal, Journal of Gastroenterology, 2012, 47, 1, 29

    CrossRef

  51. 51
    Elizabeth M. Brunt, Brent A. Neuschwander-Tetri, Alastair D. Burt, MacSween's Pathology of the Liver, 2012,

    CrossRef

  52. 52
    María-Nieves Sanz, Carlos Sánchez-Martín, Dominique Detaille, Guillaume Vial, Michel Rigoulet, Mohammed-Yehia El-Mir, Gloria Rodríguez-Villanueva, Acute Mitochondrial Actions of Glitazones on the Liver: a Crucial Parameter for their Antidiabetic Properties, Cellular Physiology and Biochemistry, 2011, 28, 5, 899

    CrossRef

  53. 53
    J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome, Current therapeutic strategies in non-alcoholic fatty liver disease, Diabetes, Obesity and Metabolism, 2011, 13, 8
  54. 54
    Anurag Maheshwari, Paul J. Thuluvath, Endocrine Diseases and the Liver, Clinics in Liver Disease, 2011, 15, 1, 55

    CrossRef

  55. 55
    John Richard, Ildiko Lingvay, Hepatic steatosis and Type 2 diabetes: current and future treatment considerations, Expert Review of Cardiovascular Therapy, 2011, 9, 3, 321

    CrossRef

  56. 56
    Amedeo Lonardo, Stefano Bellentani, Vlad Ratziu, Paola Loria, Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?, Expert Review of Gastroenterology & Hepatology, 2011, 5, 2, 279

    CrossRef

  57. 57
    Lay Gan, Shivakumar Chitturi, Geoffrey C. Farrell, Mechanisms and Implications of Age-Related Changes in the Liver: Nonalcoholic Fatty Liver Disease in the Elderly, Current Gerontology and Geriatrics Research, 2011, 2011, 1

    CrossRef

  58. 58
    Jörn M. Schattenberg, Detlef Schuppan, Nonalcoholic steatohepatitis, Current Opinion in Lipidology, 2011, 22, 6, 479

    CrossRef

  59. 59
    Brian Lam, Zobair M Younossi, Novel treatment strategies for patients with nonalcoholic fatty liver disease, Clinical Investigation, 2011, 1, 2, 229

    CrossRef

  60. 60
    Richard K. Sterling, Arun J. Sanyal, Pentoxifylline for steatohepatitis: Magic bullet or smoking gun?, Hepatology, 2011, 54, 5
  61. 61
    H. Castel, P. Mathurin, Stéatohépatite non alcoolique, EMC - Endocrinologie - Nutrition, 2011, 8, 3, 1

    CrossRef

  62. 62
    Suzanne E. Mahady, Angela C. Webster, Sarah Walker, Arun Sanyal, Jacob George, The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis, Journal of Hepatology, 2011, 55, 6, 1383

    CrossRef

  63. 63
    Vlad Ratziu, Stefano Bellentani, Helena Cortez-Pinto, Chris Day, Giulio Marchesini, A position statement on NAFLD/NASH based on the EASL 2009 special conference, Journal of Hepatology, 2010, 53, 2, 372

    CrossRef

  64. 64
    Woo Hyung Lee, Sang Geon Kim, AMPK-Dependent Metabolic Regulation by PPAR Agonists, PPAR Research, 2010, 2010, 1

    CrossRef

  65. 65
    Angel Brea Hernando, José Puzo Foncillas, Enfermedad del hígado graso no alcohólico y riesgo cardiovascular, Clínica e Investigación en Arteriosclerosis, 2010, 22, 6, 259

    CrossRef

  66. 66
    Anna Mae Diehl, Hepatic Complications of Obesity, Gastroenterology Clinics of North America, 2010, 39, 1, 57

    CrossRef

  67. 67
    S. Kaser, C. F. Ebenbichler, H. Tilg, Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease, International Journal of Clinical Practice, 2010, 64, 7
  68. 68
    P. Loria, L.E. Adinolfi, S. Bellentani, E. Bugianesi, A. Grieco, S. Fargion, A. Gasbarrini, C. Loguercio, A. Lonardo, G. Marchesini, F. Marra, M. Persico, D. Prati, G. Svegliati- Baroni, Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease, Digestive and Liver Disease, 2010, 42, 4, 272

    CrossRef

  69. 69
    Stephen A. Harrison, Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution?, Hepatology, 2010, 51, 2
  70. 70
    Mohammad S. Siddiqui, Arun J. Sanyal, Drug Therapy for NASH: Insulin-Sensitizing Agents (Metformin and Thiazolidinediones),
  71. 71
    Stephen H. Caldwell, Curtis K. Argo, Abdullah M. S. Al-Osaimi, Nonalcoholic Fatty Liver Disease,
  72. 72
    Joanna K. Dowman, Phil N. Newsome, The Chronic Liver Disease Patient,